ArticleThe International journal of social psychiatry2022
Non-pharmacological treatments for schizophrenia in Southeast Europe: An expert survey.
Article in The International journal of social psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Improving treatment of patients with psychosis in low-and-middle-income countries in Southeast Europe: Results from a hybrid effectiveness-implementation, pragmatic, cluster-randomized clinical trial (IMPULSE).European psychiatry : the journal of the Association of European Psychiatrists · 2022Trial
- Global burden of schizophrenia in 204 countries and regions from 1990 to 2021 and machine learning-based projections to 2036: an analysis of the 2021 global burden of disease study.Frontiers in psychiatry · 2025Article
- Inside the Hospitalization Voyage of Schizophrenia Care: A Single-Center Journey.Medicina (Kaunas, Lithuania) · 2024Article
- Introducing community-based mental health support in Serbia: A qualitative study on experiences and needs of long-term psychiatric users.Global mental health (Cambridge, England) · 2024Article
- Implementing psychosocial interventions within low and middle-income countries to improve community-based care for people with psychosis-A situation analysis.Frontiers in psychiatry · 2022Article
- Editorial: Psychosocial interventions in psychotic illnesses.Frontiers in psychiatry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-pharmacological treatment for schizophrenia includes educational, psychotherapeutic, social, and physical interventions. Despite growing importance of these interventions in the holistic treatment of individuals with schizophrenia, very little is known about their availability in South-East European countries (SEE).
objectiveTo explore mental health care experts' opinions of the availability of non-pharmacological treatment for people with schizophrenia in SEE.
methodsAn online survey containing 11 questions was completed by one mental health expert from each of the following SEE countries: Albania, Bosnia and Herzegovina (B&H), Bulgaria, Croatia, Greece, Kosovo
resultsIn eight countries, the estimated percentage of people with schizophrenia who receive non-pharmacological treatments was below 35%. The primary explanations for the low availability of non-pharmacological treatments were: lack of human and financial resources, lack of training for clinicians, and pharmacotherapy dominance in the treatment for schizophrenia.
conclusionLack of personal and institutional resources and state support were identified as primary obstacles to staff training and delivering non-pharmacological treatments to people with schizophrenia on individual and systemic levels, respectively. This evidence can be used to improve holistic, evidence-based treatment for schizophrenia in the SEE countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.